Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients
Objectives:. Coronavirus disease 2019 patients admitted to the ICU have high mortality. The host response to coronavirus disease 2019 has only been partially elucidated, and prognostic biomarkers have not been identified. We performed targeted proteomics on critically ill coronavirus disease 2019 pa...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer
2020-09-01
|
| Series: | Critical Care Explorations |
| Online Access: | http://journals.lww.com/10.1097/CCE.0000000000000189 |
| _version_ | 1818567954163302400 |
|---|---|
| author | Douglas D. Fraser, MD, PhD Gediminas Cepinskas, DVM, PhD Eric K. Patterson, PhD Marat Slessarev, MD, MSc Claudio Martin, MD, MSc Mark Daley, PhD Maitray A. Patel, BSc Michael R. Miller, PhD David B. O’Gorman, PhD Sean E. Gill, PhD Guillaume Pare, MD, MSc Ioannis Prassas, PhD Eleftherios Diamandis, MD, PhD on behalf of the Lawson COVID19 Study Team Robert Arntfield Ian Ball Gordon Barkwell Tracey Bentall Karen Bosma Saoirse Cameron Eileen Campbell David Carter Carolina Gillio-Meina Robert Hegele Natalya Odoardi Ram Singh Kelly Summers Sue Tereschyn |
| author_facet | Douglas D. Fraser, MD, PhD Gediminas Cepinskas, DVM, PhD Eric K. Patterson, PhD Marat Slessarev, MD, MSc Claudio Martin, MD, MSc Mark Daley, PhD Maitray A. Patel, BSc Michael R. Miller, PhD David B. O’Gorman, PhD Sean E. Gill, PhD Guillaume Pare, MD, MSc Ioannis Prassas, PhD Eleftherios Diamandis, MD, PhD on behalf of the Lawson COVID19 Study Team Robert Arntfield Ian Ball Gordon Barkwell Tracey Bentall Karen Bosma Saoirse Cameron Eileen Campbell David Carter Carolina Gillio-Meina Robert Hegele Natalya Odoardi Ram Singh Kelly Summers Sue Tereschyn |
| author_sort | Douglas D. Fraser, MD, PhD |
| collection | DOAJ |
| description | Objectives:. Coronavirus disease 2019 patients admitted to the ICU have high mortality. The host response to coronavirus disease 2019 has only been partially elucidated, and prognostic biomarkers have not been identified. We performed targeted proteomics on critically ill coronavirus disease 2019 patients to better understand their pathophysiologic mediators and to identify potential outcome markers.
Design:. Blood was collected at predetermined ICU days for proximity extension assays to determine the plasma concentrations of 1,161 proteins.
Setting:. Tertiary care ICU and academic laboratory.
Subjects:. All patients admitted to the ICU suspected of being infected with severe acute respiratory syndrome coronavirus 2, using standardized hospital screening methodologies, had blood samples collected until either testing was confirmed negative on ICU day 3 (coronavirus disease 2019 negative) or until ICU day 10 if the patient positive (coronavirus disease 2019 positive).
Interventions:. None.
Measurements and Main Results:. Age- and sex-matched healthy control subjects and ICU patients who were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well-balanced with the exception that coronavirus disease 2019 positive patients suffered bilateral pneumonia more frequently than coronavirus disease 2019 negative patients. Mortality rate for coronavirus disease 2019 positive ICU patients was 40%. Feature selection identified the top performing proteins for identifying coronavirus disease 2019 positive ICU patients from both healthy control subjects and coronavirus disease 2019 negative ICU patients (classification accuracies 100%). The coronavirus disease 2019 proteome was dominated by interleukins and chemokines, as well as several membrane receptors linked to lymphocyte-associated microparticles and/or cell debris. Mortality was predicted for coronavirus disease 2019 positive patients based on plasma proteome profiling on both ICU day 1 (accuracy 92%) and ICU day 3 (accuracy 83%). Promising prognostic proteins were then narrowed down to six, each of which provided excellent classification performance for mortality when measured on ICU day 1 CMRF-35-like molecule, interleukin receptor-12 subunit B1, cluster of differentiation 83 [CD83], family with sequence similarity 3, insulin-like growth factor 1 receptor and opticin; area-under-the-curve =1.0; p = 0.007).
Conclusions:. Targeted proteomics with feature classification easily distinguished both healthy control subjects and coronavirus disease 2019 tested negative ICU patients from coronavirus disease 2019 tested positive ICU patients. Multiple proteins were identified that accurately predicted coronavirus disease 2019 tested positive patient mortality. |
| first_indexed | 2024-12-14T06:29:56Z |
| format | Article |
| id | doaj.art-cccc0cb28a5d481eb92f663806d7c95a |
| institution | Directory Open Access Journal |
| issn | 2639-8028 |
| language | English |
| last_indexed | 2024-12-14T06:29:56Z |
| publishDate | 2020-09-01 |
| publisher | Wolters Kluwer |
| record_format | Article |
| series | Critical Care Explorations |
| spelling | doaj.art-cccc0cb28a5d481eb92f663806d7c95a2022-12-21T23:13:33ZengWolters KluwerCritical Care Explorations2639-80282020-09-0129e018910.1097/CCE.0000000000000189202009000-00002Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 PatientsDouglas D. Fraser, MD, PhD0Gediminas Cepinskas, DVM, PhD1Eric K. Patterson, PhD2Marat Slessarev, MD, MSc3Claudio Martin, MD, MSc4Mark Daley, PhD5Maitray A. Patel, BSc6Michael R. Miller, PhD7David B. O’Gorman, PhD8Sean E. Gill, PhD9Guillaume Pare, MD, MSc10Ioannis Prassas, PhD11Eleftherios Diamandis, MD, PhD12on behalf of the Lawson COVID19 Study TeamRobert ArntfieldIan BallGordon BarkwellTracey BentallKaren BosmaSaoirse CameronEileen CampbellDavid CarterCarolina Gillio-MeinaRobert HegeleNatalya OdoardiRam SinghKelly SummersSue Tereschyn1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.7 Computer Science, Western University, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.1 Lawson Health Research Institute, London, ON, Canada.11 Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.12 Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.12 Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada.Objectives:. Coronavirus disease 2019 patients admitted to the ICU have high mortality. The host response to coronavirus disease 2019 has only been partially elucidated, and prognostic biomarkers have not been identified. We performed targeted proteomics on critically ill coronavirus disease 2019 patients to better understand their pathophysiologic mediators and to identify potential outcome markers. Design:. Blood was collected at predetermined ICU days for proximity extension assays to determine the plasma concentrations of 1,161 proteins. Setting:. Tertiary care ICU and academic laboratory. Subjects:. All patients admitted to the ICU suspected of being infected with severe acute respiratory syndrome coronavirus 2, using standardized hospital screening methodologies, had blood samples collected until either testing was confirmed negative on ICU day 3 (coronavirus disease 2019 negative) or until ICU day 10 if the patient positive (coronavirus disease 2019 positive). Interventions:. None. Measurements and Main Results:. Age- and sex-matched healthy control subjects and ICU patients who were either coronavirus disease 2019 positive or coronavirus disease 2019 negative were enrolled. Cohorts were well-balanced with the exception that coronavirus disease 2019 positive patients suffered bilateral pneumonia more frequently than coronavirus disease 2019 negative patients. Mortality rate for coronavirus disease 2019 positive ICU patients was 40%. Feature selection identified the top performing proteins for identifying coronavirus disease 2019 positive ICU patients from both healthy control subjects and coronavirus disease 2019 negative ICU patients (classification accuracies 100%). The coronavirus disease 2019 proteome was dominated by interleukins and chemokines, as well as several membrane receptors linked to lymphocyte-associated microparticles and/or cell debris. Mortality was predicted for coronavirus disease 2019 positive patients based on plasma proteome profiling on both ICU day 1 (accuracy 92%) and ICU day 3 (accuracy 83%). Promising prognostic proteins were then narrowed down to six, each of which provided excellent classification performance for mortality when measured on ICU day 1 CMRF-35-like molecule, interleukin receptor-12 subunit B1, cluster of differentiation 83 [CD83], family with sequence similarity 3, insulin-like growth factor 1 receptor and opticin; area-under-the-curve =1.0; p = 0.007). Conclusions:. Targeted proteomics with feature classification easily distinguished both healthy control subjects and coronavirus disease 2019 tested negative ICU patients from coronavirus disease 2019 tested positive ICU patients. Multiple proteins were identified that accurately predicted coronavirus disease 2019 tested positive patient mortality.http://journals.lww.com/10.1097/CCE.0000000000000189 |
| spellingShingle | Douglas D. Fraser, MD, PhD Gediminas Cepinskas, DVM, PhD Eric K. Patterson, PhD Marat Slessarev, MD, MSc Claudio Martin, MD, MSc Mark Daley, PhD Maitray A. Patel, BSc Michael R. Miller, PhD David B. O’Gorman, PhD Sean E. Gill, PhD Guillaume Pare, MD, MSc Ioannis Prassas, PhD Eleftherios Diamandis, MD, PhD on behalf of the Lawson COVID19 Study Team Robert Arntfield Ian Ball Gordon Barkwell Tracey Bentall Karen Bosma Saoirse Cameron Eileen Campbell David Carter Carolina Gillio-Meina Robert Hegele Natalya Odoardi Ram Singh Kelly Summers Sue Tereschyn Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients Critical Care Explorations |
| title | Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients |
| title_full | Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients |
| title_fullStr | Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients |
| title_full_unstemmed | Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients |
| title_short | Novel Outcome Biomarkers Identified With Targeted Proteomic Analyses of Plasma From Critically Ill Coronavirus Disease 2019 Patients |
| title_sort | novel outcome biomarkers identified with targeted proteomic analyses of plasma from critically ill coronavirus disease 2019 patients |
| url | http://journals.lww.com/10.1097/CCE.0000000000000189 |
| work_keys_str_mv | AT douglasdfrasermdphd noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT gediminascepinskasdvmphd noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT erickpattersonphd noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT maratslessarevmdmsc noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT claudiomartinmdmsc noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT markdaleyphd noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT maitrayapatelbsc noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT michaelrmillerphd noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT davidbogormanphd noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT seanegillphd noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT guillaumeparemdmsc noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT ioannisprassasphd noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT eleftheriosdiamandismdphd noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT onbehalfofthelawsoncovid19studyteam noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT robertarntfield noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT ianball noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT gordonbarkwell noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT traceybentall noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT karenbosma noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT saoirsecameron noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT eileencampbell noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT davidcarter noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT carolinagilliomeina noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT roberthegele noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT natalyaodoardi noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT ramsingh noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT kellysummers noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients AT suetereschyn noveloutcomebiomarkersidentifiedwithtargetedproteomicanalysesofplasmafromcriticallyillcoronavirusdisease2019patients |